Fundraising Fox

NextCure

NASDAQ: NXTC

Beltsville, US · Founded 2015 · Delaware corporation · 9 known investors

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

Founders & leadership

NextCure was founded in 2015 by Michael Richman.

MR
Michael RichmanFounder
TM
Timothy MayerinExecutive
UGUdayan Guha
Udayan GuhainExecutive
SP
Steven P. CobourninCFO
SKSourav Kundu
Sourav KunduinExecutive
KS
Kevin ShawinExecutive
AR
ASHER RUBINExecutive

Board

EV
Elaine V. JonesBoard director
AB
Anne BorgmanBoard director
DKDavid Kabakoff
David KabakoffBoard directorExecutive Partner, Private Equity at Sofinnova Ventures
TSTIM SHANNON
TIM SHANNONin𝕏Board directorGeneral Partner at Canaan Partners
JL
JUDITH LIBoard directorPartner at LAV

Investors · 9

Funding

SEC filings, press & company announcements

$449.9M disclosed across 4 rounds · 2015–2026

$21.5MraisedDec 2025 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy MayerExecutive Officer
  • Michael RichmanExecutive Officer, Director
  • Elaine V. JonesDirector
  • Udayan GuhaExecutive Officer
  • Anne BorgmanDirector
  • Steven P. CobournExecutive Officer
  • David KabakoffDirector
  • Sourav KunduExecutive Officer
  • Ellen FeigalDirector
  • Stephen WebsterDirector
  • John G. HoustonDirector
  • Kevin ShawExecutive Officer
Offering amount
$21.5M
Amount sold
$21.5M
Finders' fees
$1.2M
Placement agents
H.C. Wainwright & Co., LLC
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$93.4MraisedNov 2018 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stella XuDirector
  • Michael RichmanExecutive Officer, Director
  • Michael YiDirector
  • Judith LiDirector
  • Chau Q. KhuongDirector
  • Kevin N. HellerExecutive Officer
  • David KabakoffDirector
  • Steven CobournExecutive Officer
  • Tim ShannonDirector
  • Elaine JonesDirector
Offering amount
$93.4M
Amount sold
$93.4M
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$15MraisedJan 2016 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CAROLYN GREENDirector
  • ASHER RUBINExecutive Officer
  • DAVID KABAKOFFDirector
  • TIM SHANNONDirector
  • MICHAEL RICHMANExecutive Officer, Director
  • JUDITH LIDirector
  • CHAU Q. KHUONGDirector
Offering amount
$67M
Amount sold
$15M
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Frequently asked questions

What does NextCure do?
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
Who founded NextCure?
NextCure was founded by Michael Richman in 2015.
Who are NextCure's investors?
NextCure's investors include Bay City Capital, Canaan Partners, LAV, Lilly Asia Ventures, Pfizer Venture Investments, Quan Capital, Sofinnova Ventures, Taiho Ventures, LLC and 1 more.
How much funding has NextCure raised?
NextCure has disclosed $449.9M raised across 4 rounds.
Where is NextCure headquartered?
NextCure is headquartered in Beltsville, US.